Login / Signup

Placebo-Controlled, Double-Blind Study of Empagliflozin (EMPA) and Implantable Cardioverter-Defibrillator (EMPA-ICD) in Patients with Type 2 Diabetes (T2DM): Rationale and Design.

Shinya FujikiKenichi IijimaMasaaki OkabeShinichi NiwanoKenichi TsujitaShigeto NaitoKenji AndoKengo KusanoRitsushi KatoJunichi NittaTetsuji MiuraTakeshi MitsuhashiKazuomi KarioYusuke KondoMasaki IedaNobuhisa HagiwaraToyoaki MuroharaKazuyoshi TakahashiHirofumi TomitaYasuchika TakeishiToshihisa AnzaiWataru ShimizuMasafumi WatanabeYoshihiro MorinoTakeshi KatoHiroshi TadaYoshihisa NakagawaMasafumi YanoKoji MaemuraTakeshi KimuraHisako YoshidaKeiko OtaTakahiro TanakaNobutaka KitamuraKoichi NodeYoshifusa AizawaIppei ShimizuDaisuke IzumiKazuyuki OzakiTohru Minaminonull null
Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2020)
Unique trial number, jRCTs031180120 ( https://jrct.niph.go.jp/latest-detail/jRCTs031180120 ).
Keyphrases
  • placebo controlled
  • double blind
  • phase iii
  • phase ii
  • study protocol
  • clinical trial
  • randomized controlled trial
  • phase ii study
  • type diabetes
  • weight loss
  • adipose tissue
  • glycemic control
  • rectal cancer